6
Participants
Start Date
December 22, 2015
Primary Completion Date
December 18, 2017
Study Completion Date
December 18, 2017
Tetracycline
Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.
Demeclocycline
Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.
Total Hip Replacement
Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.
Helen Hayes Hospital, West Haverstraw
Research Site, West Haverstraw
Lead Sponsor
Amgen
INDUSTRY